Advantages
Australia is an attractive destination to undertake health and medical research.
There are many benefits to conducting clinical trials in Australia, including:
- world-leading researchers and health professionals
- strong research infrastructure that supports multicentre studies and teletrials
- world class health and medical system
- streamlined ethics and governance process supported by regulatory oversight which promotes translational research
- stable socio-political environment
- high standards that support integrity of trial operations
- robust intellectual property system
- a diverse patient demographic that supports globally relevant results
- health care aligned with internationally accepted standards and guidelines
- investment and cost incentives
- established early and late phase trial capability.
High-quality research, facilities and manufacturing
Australia has a strong reputation for excellence in scientific and medical research, supported by world-class hospitals, research institutes and universities. Australia is internationally recognised for its highly trained clinical and scientific workforce and the high-quality data produced by skilled and experienced research teams.
Our high-quality clinical research facilities have state-of-the-art equipment for testing, treatment and analysis. Australia also has advanced manufacturing capability which supports research from early phase through to late-stage trials.
The quality of clinical research in Australia is internationally recognised and provides confidence in findings of clinical trials conducted in Australia.
Standards of conduct
Clinical trials in Australia follow accepted international good clinical practice (GCP) standards of conduct aligned with:
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice
- International Organization for Standardization (ISO) 14155 Clinical Investigation of Medical Devices for Human Subjects - Good Clinical Practice
- World Health Organization International Clinical Trials Registry Platform.
Australia applies GCP standards using a risk‑proportionate, modern approach consistent with current ICH guidance. This ensures clinical trial data generated in Australia are robust, inspection‑ready, and routinely accepted by major regulators, including the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and Health Canada. Many Australian researchers have international experience and are experienced in applying GCP and other guidelines.
Australian clinical trials adhere to:
- Australian clinical trial handbook
- Australian Code for the Responsible Conduct of Research
- National Clinical Trials Governance Framework which embeds clinical trial services into the routine provision of health services. It strengthens governance for clinical trials, provides clarity to those who deliver them, and helps to drive national consistency
- The National Standard Operating Procedures for Clinical Trials in Australia which outline the minimum standards to be followed when conducting clinical trials.
Regulation, systems and processes
Australia has a fast and pragmatic regulatory pathway for clinical trials. In Australia, an ethics committee reviews research proposals that involve human participants to ensure they meet ethical standards and guidelines.
The laws and regulations shaping health research include the national:
- Therapeutic Goods Act 1989
- Privacy Act 1988
- Research Involving Human Embryos Act 2002
- Therapeutic Goods Regulations 1990
- Therapeutic Goods (Medical Devices) Regulations 2002.
The National Statement on Ethical Conduct in Human Research is the Australian ethical standard against which all research involving humans, including clinical trials, are reviewed.
The ICH Guideline for Good Clinical Practice is incorporated into Australian law (without modification) by reference in the Therapeutic Goods Regulations 1990. To assist stakeholders in complying with ICH Guideline for Good Clinical Practice the Therapeutic Goods Administration (TGA) provides comments in accordance with local regulatory requirements.
The TGA regulates access to ‘unapproved’ therapeutic goods in clinical trials through two schemes:
- Clinical Trial Notification (CTN) scheme – requires approval by an ethics committee and institutional authorisations, which considers trial design, the potential risks and ethical acceptability
- Clinical Trial Approval (CTA) scheme – requires TGA review in addition to ethics approval, prior to the start of the clinical trial.
These schemes significantly reduce the Sponsor’s up-front documentation burden required for a clinical trial application in comparison to international requirements for an Investigational New Drug (IND) submission.
Clinical trials that do not involve the use of ‘unapproved’ therapeutic goods are not subject to the requirements of the CTN and CTA schemes.
More information about the schemes is available on the TGA's website.
Australia uses standard contract templates and consistent processes to streamline clinical trial operations.
Safety monitoring and reporting in Australian clinical trials involve continuous tracking of adverse events and immediate reporting of serious adverse events to regulatory bodies and ethics committees.
Diverse and accessible population
Australia is a multicultural country with:
- a diverse population that can meet recruitment needs, 31% of Australians are born overseas and 48% of Australians have a parent born overseas
- an informed and willing population of potential trial participants
- high clinical trial participation per capita.
Australian clinical practices and some aspects of its healthcare system are similar to other OECD nations. Our diverse population means researchers can recruit a similar patient population to those countries.
Australia has inclusive recruitment practices and flexible trial models, including telehealth options. This promotes active engagement with First Nations and geographically dispersed communities.
The Australian Institute of Health and Welfare collects:
- statistics on Australian risk factors, diseases and death in Australia
- links to online data collections, which can provide useful information for sponsors considering placing trials in Australia.
Investment and cost incentives
The Australian Government’s Research and Development (R&D) Tax Incentive encourages more industry investment in research and development. The incentive provides businesses investing in eligible research and development with generous tax offsets.
Australia offers competitive grant opportunities for health and medical research projects through the Medical Research Future Fund (MRFF) and National Health and Medical Research Council (NHMRC). These include international clinical trial opportunities to promote global collaboration and extension of cohort trials to Australia.
Seasonal differences
Seasonal differences between the northern and southern hemispheres allow trials dependent on seasonal factors to be conducted or continued in Australia, extending periods for patient recruitment. Examples include clinical trials for flu vaccines, allergy and respiratory diseases.
Strategic location
Positioned in the Asia-Pacific region, Australia is an ideal hub for trials in the region and offers proximity to key markets. Australia supports globally coordinated development programs and is recognised as a global leader for early phase and first‑in‑human trials.
Reforms to the operating environment
To ensure Australia remains a world leader in health and medical research, we are working with state and territory governments on national reforms to improve the clinical trial operating environment. This work will ensure a stronger, easier and more consistent national approach to health research. A key initiative of our modernisation and efficiency reforms is the National One Stop Shop.
More information
- MTP Connect – Australia's growth centre for the medical technologies, biotechnologies and pharmaceuticals sectors.
- AusBiotech – dedicated to promoting Australia as a key destination to conduct clinical trials.
- Medical Technology Association of Australia (MTAA) – the peak association representing companies in the medical technology industry.
- ARCS Australia – the peak body for the life sciences sector in Australia, driving capability and excellence across clinical trials and the therapeutic product lifecycle.